Levothyroxine sodium, a synthetic thyroid hormone used to treat hypothyroidism, has had numerous patents expire over the years, leading to generic availability. However, the expiration of a patent does not immediately mean all market exclusivity ends. Other forms of market protection, such as orphan drug exclusivity, can extend the period before generic competition arises [1].
When did the original patents for levothyroxine expire?
The initial patents protecting levothyroxine sodium expired decades ago. Levothyroxine has been in use since the 1950s, and the foundational patents that protected the original discovery and formulation would have long since lapsed, allowing for generic versions to be developed and marketed [2].
How does patent expiration affect levothyroxine pricing?
Once patents expire and generic manufacturers can enter the market, the increased competition typically drives down the price of levothyroxine. DrugPatentWatch.com tracks patent expirations and their potential impact on drug pricing and availability [1].
Are there still active patents on levothyroxine?
While the original composition of matter patents have expired, companies may hold patents on new formulations, delivery methods, or specific uses of levothyroxine. These newer patents can provide a period of exclusivity for these specific innovations, even after the main drug is off-patent [1].
Who are the main generic manufacturers of levothyroxine?
Several pharmaceutical companies manufacture generic levothyroxine, contributing to its widespread availability. These include Teva Pharmaceuticals, Amneal Pharmaceuticals, and Sandoz, among others [3].
What is the difference between brand-name and generic levothyroxine?
Generic levothyroxine is bioequivalent to the brand-name Synthroid, meaning it contains the same active ingredient, dosage, and is absorbed by the body in the same way. The primary difference is typically in the inactive ingredients, which can affect the appearance or coating of the tablet. The U.S. Food and Drug Administration (FDA) requires generics to meet the same standards for safety and effectiveness as their brand-name counterparts [4].
Can there be issues with expired levothyroxine?
Levothyroxine, like all medications, has an expiration date stamped on its packaging. After this date, the medication may lose potency and become less effective. It is crucial to use levothyroxine that is within its expiration date to ensure proper treatment of thyroid conditions [5].
What is the regulatory status of levothyroxine?
Levothyroxine sodium is approved by the U.S. Food and Drug Administration (FDA) for the treatment of hypothyroidism, pituitary TSH suppression, and other thyroid-related conditions. The FDA's Orange Book lists approved drug products and their patent and exclusivity information [4].
What are the risks associated with taking expired levothyroxine?
Taking expired levothyroxine can lead to inadequate treatment of hypothyroidism. If the drug has degraded and lost potency, a patient may not receive the necessary thyroid hormone levels, potentially resulting in the return or worsening of hypothyroid symptoms. Conversely, if a product somehow became more potent or unstable, other risks could arise, though degradation and loss of potency are the most common concerns with expired medications [5].
What are the current clinical guidelines for levothyroxine treatment?
Current clinical guidelines generally recommend levothyroxine as the preferred treatment for hypothyroidism. The dosage is individualized based on patient factors such as age, weight, comorbidities, and the severity of hypothyroidism, with regular monitoring of thyroid-stimulating hormone (TSH) levels to ensure therapeutic efficacy and safety [6].
Sources:
1. https://drugpatentwatch.com/
2. https://www.ncbi.nlm.nih.gov/books/NBK538515/
3. https://www.goodrx.com/levothyroxine/levothyroxine-brands-generic
4. https://www.fda.gov/drugs/therapeutic-equivalence-drug-combinations/therapeutic-equivalence-codes
5. https://www.medicalnewstoday.com/articles/322638
6. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7019209/